Patents by Inventor Kyle J. Eastman

Kyle J. Eastman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE
    Publication number: 20250136619
    Abstract: The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from mTor, PLK1, CDKI, CDK2, CDK9, BRD4, AURKA, AURKB, MEK, Src, c-KIT, KIF11, HSP90, tubulin, proteasome, topoisomerase or HD AC which is linked to a moiety that binds to a target protein selected from KRAS, HER2 or EGFR. Pharmaceutical compositions and their use in treating disease, such as cancer, are also disclosed.
    Type: Application
    Filed: October 4, 2022
    Publication date: May 1, 2025
    Inventors: Samuel W. GERRITZ, Katherine J. KAYSER-BRICKER, Kyle J. EASTMAN, Taavi NEKLESA, Kanak Shail RAINA, James John MOUSSEAU, Nilesh ZAWARE
  • HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE
    Publication number: 20250136611
    Abstract: The invention provides heterobifunctional compounds, pharmaceutical compositions, and their use treating disease, such as cancer.
    Type: Application
    Filed: October 18, 2024
    Publication date: May 1, 2025
    Inventors: Kyle J. Eastman, Katherine J. Kayser-Bricker, James John Mousseau, Kanak Shail Raina
  • HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE
    Publication number: 20250032623
    Abstract: The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from mTor, PLK1, CDK1, CDK2, CDK9, BRD4, AURKA, AURKB, MEK, Src, c-KIT, KIF11, HSP90, tubulin, proteasome, topoisomerase or HD AC which is linked to a moiety that binds to a target protein selected from BTK, androgen receptor or IDH1. Pharmaceutical compositions and their use in treating disease, such as cancer, are also disclosed.
    Type: Application
    Filed: October 4, 2022
    Publication date: January 30, 2025
    Inventors: Samuel W. GERRITZ, Katherine J. KAYSER-BRICKER, Kyle J. EASTMAN, Taavi NEKLESA, Kanak Shail RAINA
  • HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE
    Publication number: 20240408093
    Abstract: The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from GSPT1, Cyclin K, RBM23, RBM39, IKZF1, IKZF3, PLK1, CDK4 or CK1alpha which is linked to a moiety that binds to a target protein selected from KRAS, HER2, EGFR, androgen receptor protein, estrogen receptor protein, ALK, IDH1, FLT3, FGFR1, FGFR4, FGFR2, FGFR3, ERK1, ERK2, FGR, HER3 or HER4. Pharmaceutical compositions and their use in treating disease, such as cancer, are also disclosed.
    Type: Application
    Filed: October 4, 2022
    Publication date: December 12, 2024
    Inventors: Samuel W. GERRITZ, Katherine J. KAYSER-BRICKER, Taavi NEKLESA, David E. PULEO, James John MOUSSEAU, Nilesh ZAWARE, Kyle J. EASTMAN
  • Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
    Patent number: 12162860
    Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    Type: Grant
    Filed: May 11, 2023
    Date of Patent: December 10, 2024
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang, Joel Charles Barrish, William Greenlee, Kyle J. Eastman
  • HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE
    Publication number: 20240238424
    Abstract: The invention provides heterobifunctional compounds, pharmaceutical compositions, and their use in protein degradation and treating disease, such as cancer.
    Type: Application
    Filed: November 21, 2023
    Publication date: July 18, 2024
    Inventors: Samuel W. GERRITZ, Kyle J. EASTMAN, Katherine J KAYSHER-BRICKER, Taavi NEKLESA, Kanak Shail RAINA, Hao LI, James John MOUSSEAU, Nilesh K. ZAWARE
  • Pharmaceutical compounds for treatment of medical disorders
    Patent number: 12006307
    Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    Type: Grant
    Filed: July 25, 2022
    Date of Patent: June 11, 2024
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang, Joel Charles Barrish, William Greenlee, Kyle J. Eastman
  • MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
    Publication number: 20240059702
    Abstract: Macrocyclic Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, and Formula VIII or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    Type: Application
    Filed: May 11, 2023
    Publication date: February 22, 2024
    Applicant: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan WILES, Avinash S. PHADKE, Dawei CHEN, Venkat Rao GADHACHANDA, Joel Charles BARRISH, Atul AGARWAL, Kyle J. EASTMAN
  • Macrocyclic compounds for the treatment of medical disorders
    Patent number: 11814391
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein reduce excessive activation of complement.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: November 14, 2023
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Venkat Rao Gadhachanda, Kyle J. Eastman, Godwin Pais
  • ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
    Publication number: 20230357199
    Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    Type: Application
    Filed: May 11, 2023
    Publication date: November 9, 2023
    Inventors: Jason Allan WILES, Avinash S. PHADKE, Milind DESHPANDE, Atul AGARWAL, Dawei CHEN, Venkat Rao GADHACHANDA, Akihiro HASHIMOTO, Godwin PAIS, Qiuping WANG, Xiangzhu WANG, Joel Charles BARRISH, William GREENLEE, Kyle J. EASTMAN
  • Macrocyclic compounds for treatment of medical disorders
    Patent number: 11718626
    Abstract: Macrocyclic Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, and Formula VIII or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: August 8, 2023
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Dawei Chen, Venkat Rao Gadhachanda, Joel Charles Barrish, Atul Agarwal, Kyle J. Eastman
  • Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
    Patent number: 11708351
    Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: July 25, 2023
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang, Joel Charles Barrish, William Greenlee, Kyle J. Eastman
  • PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS
    Publication number: 20230085372
    Abstract: This disclosure provides pharmaceutical compounds to treat medical disorders, such as complement-mediated disorders, including complement Cl-mediated disorders.
    Type: Application
    Filed: March 20, 2020
    Publication date: March 16, 2023
    Applicant: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Venkat Rao Gadhachanda, Kyle J. Eastman
  • PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
    Publication number: 20230071620
    Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    Type: Application
    Filed: July 25, 2022
    Publication date: March 9, 2023
    Inventors: Jason Allan WILES, Avinash S. PHADKE, Milind DESHPANDE, Atul AGARWAL, Dawei CHEN, Venkat Rao GADHACHANDA, Akihiro HASHIMOTO, Godwin PAIS, Qiuping WANG, Xiangzhu WANG, Joel Charles BARRISH, William GREENLEE, Kyle J. EASTMAN
  • PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS
    Publication number: 20230022157
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein reduce the excessive activation of complement.
    Type: Application
    Filed: August 20, 2019
    Publication date: January 26, 2023
    Applicant: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Venkat Rao Gadhachanda, Kyle J. Eastman, Godwin Pais
  • ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
    Publication number: 20220396563
    Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    Type: Application
    Filed: July 2, 2021
    Publication date: December 15, 2022
    Inventors: Jason Allan WILES, Avinash S. PHADKE, Milind DESHPANDE, Atul AGARWAL, Dawei CHEN, Venkat Rao GADHACHANDA, Akihiro HASHIMOTO, Godwin PAIS, Qiuping WANG, Xiangzhu WANG, Joel Charles BARRISH, William GREENLEE, Kyle J. EASTMAN
  • MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
    Publication number: 20220380380
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein reduce excessive activation of complement.
    Type: Application
    Filed: September 6, 2019
    Publication date: December 1, 2022
    Applicant: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Venkat Rao Gadhachanda, Kyle J. Eastman, Godwin Pais
  • Pharmaceutical compounds for treatment of medical disorders
    Patent number: 11447465
    Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: September 20, 2022
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang, Joel Charles Barrish, William Greenlee, Kyle J. Eastman
  • MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
    Publication number: 20210300934
    Abstract: Macrocyclic Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, and Formula VIII or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    Type: Application
    Filed: May 7, 2021
    Publication date: September 30, 2021
    Inventors: Jason Allan WILES, Avinash S. PHADKE, Dawei CHEN, Venkat Rao GADHACHANDA, Joel Charles BARRISH, Atul AGARWAL, Kyle J. EASTMAN
  • Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
    Patent number: 11084800
    Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: August 10, 2021
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang, Joel Charles Barrish, William Greenlee, Kyle J. Eastman